Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Japan/Korea Joint Phase II Study of Nimotuzumab plus Irinotecan in Advanced or Recurrent Gastric Cancer
jRCT2080220818Phase 2
- Sponsor
- Daiichi Sankyo Co., Ltd.
- Start
- Aug 2009
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of nimotuzumab in gastric adenocarcinoma, sponsored by Daiichi Sankyo Co., Ltd.
02
Drugs
nimotuzumab
03
Conditions
gastric adenocarcinoma
Beyond the preview
Go deeper on jRCT2080220818.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080220818.